Nanomedicine against Alzheimer’s and Parkinson’s Disease

Author(s): Ankit Tandon, Sangh J. Singh, Rajnish K. Chaturvedi*

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 12 , 2021

Become EABM
Become Reviewer
Call for Editor


Alzheimer’s and Parkinson’s are the two most rampant neurodegenerative disorders worldwide. Existing treatments have a limited effect on the pathophysiology but are unable to fully arrest the progression of the disease. This is due to the inability of these therapeutic molecules to efficiently cross the blood-brain barrier. We discuss how nanotechnology has enabled researchers to develop novel and efficient nano-therapeutics against these diseases. The development of nanotized drug delivery systems has permitted an efficient, site-targeted, and controlled release of drugs in the brain, thereby presenting a revolutionary therapeutic approach. Nanoparticles are also being thoroughly studied and exploited for their role in the efficient and precise diagnosis of neurodegenerative conditions. We summarize the role of different nano-carriers and RNAi-conjugated nanoparticle-based therapeutics for their efficacy in pre-clinical studies. We also discuss the challenges underlying the use of nanomedicine with a focus on their route of administration, concentration, metabolism, and any toxic effects for successful therapeutics in these diseases.

Keywords: Nanomedicine, alzheimer's disease, parkinson's disease, nanoparticles, neurodegenerative disease, apoptosis, neuroinflammation, neurodegenerative disease.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 21 October, 2020
Page: [1507 - 1545]
Pages: 39
DOI: 10.2174/1381612826666201021140904
Price: $65

Article Metrics

PDF: 157